Lloyd Klickstein Net Worth

Lloyd Klickstein biography

Dr. Lloyd Klickstein M.D., Ph.D. serves as Chief Scientific Officer of the Company. Dr. Klickstein brings to resTORbio a strong background in drug discovery and development for new clinical indications with high unmet medical need. Prior to joining resTORbio, Dr. Klickstein was the Global Head of Translational Medicine for the New Indication Discovery Unit and the Exploratory Disease Area at Novartis Institutes for Biomedical Research, where he led teams that brought forward multiple innovative programs in a wide array of therapeutic areas including the research and development of small molecules for nonalcoholic steatohepatitis, gene therapy for hearing loss, gene editing for sickle cell anemia, and TORC1 inhibitors for diseases of aging. Before Novartis, Dr. Klickstein was an academic physician-scientist at Brigham and Women's Hospital (BWH), where he directed a basic research laboratory funded by the National Institutes of Health and maintained an active clinical practice in the Arthritis Center. Klickstein received a B.S. from Tufts University and an M.D. and Ph.D. from Harvard University. He completed post-graduate clinical training in Internal Medicine, Rheumatology & Immunology at BWH and a post-doctoral research fellowship at the Center for Blood Research in Boston, MA.

What is the salary of Lloyd Klickstein?

As the Chief Scientific Officer of resTORbio, the total compensation of Lloyd Klickstein at resTORbio is $2,415,320. There are 1 executives at resTORbio getting paid more, with Chen Schor having the highest compensation of $2,778,240.

How old is Lloyd Klickstein?

Lloyd Klickstein is 63, he's been the Chief Scientific Officer of resTORbio since 2019. There are 1 older and 5 younger executives at resTORbio. The oldest executive at resTORbio, Inc. is Jeffrey Chodakewitz, 64, who is the Independent Director.

What's Lloyd Klickstein's mailing address?

Lloyd's mailing address filed with the SEC is C/O RESTORBIO, INC., 500 BOYLSTON STREET, 13TH FLOOR, BOSTON, MA, 02116.

Insiders trading at resTORbio

Over the last 7 years, insiders at resTORbio have traded over $9,290,741 worth of resTORbio stock and bought 1,305,999 units worth $19,553,525 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Health Llc Pure Tech oraz Jonathan Silverstein. On average, resTORbio executives and independent directors trade stock every 69 days with the average trade being worth of $22,102,789. The most recent stock trade was executed by Health Llc Pure Tech on 18 December 2019, trading 6,161,531 units of TORC stock currently worth $7,393,837.

What does resTORbio do?

resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.

resTORbio executives and stock owners

resTORbio executives and other stock owners filed with the SEC include:

• Chen Schor,
  President, Chief Executive Officer, Secretary, Director
• Lloyd Klickstein,
  Chief Scientific Officer
• Jeffrey Chodakewitz,
  Independent Director
• Yair Chaim Schindel,
  Director
• Aya Jakobovits,
  Director
• Carl Gordon,
  Director
• Steve Dubin,
  Director
• Erez Chimovits,
  Director
• Don Healey,
  Chief Technology Officer
• Francesco Galimi,
  Senior Vice President and Chief Medical Officer
• Carrie Krehlik,
  Chief Human Resource Officer, Senior Vice President
• Stewart Abbot,
  Chief Operating Officer, Senior Vice President, Chief Scientific Officer
• Health Llc Pure Tech,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• John J Mccabe,
  Vice President, Finance
• Meredith Manning,
  Chief Commercial Officer
• Michael Grissinger,
  Director
• Joan Mannick,
  Chief Medical Officer
• Paul R. Fonteyne,
  Director
• David Adam Steinberg,
  Director
• Lynne Marie Sullivan,
  Director
• Jonathan Silverstein,
  Director